Boehringer Ingelheim is closely held, owned mainly by members of three families, but it tries to compete with its large pharma peers in a broad range of priority therapeutic areas, an effort it bolsters through business development, particularly partnering and licensing. At the LSX World Congress USA meeting in Boston recently, Andrew Whittle, the German firm’s US-based director of business development and licensing, talked about BI’s dealmaking philosophy.
Recent Deal Coverage
New text that we're going to link here
Newron has received "several indications of interest" in evenamide, which is being prepped to go into Phase III for treatment-resistant schizophrenia.
Chinese Firms To Dominate Domestic Cell Therapy Market As Gilead Exits
The company has business development teams in both the US and Europe, Whittle said, along with offices in Asia and...
